MerLion's lead drug finafloxacin moves into Phase III through Alcon
This article was originally published in Scrip
Executive Summary
MerLion Pharmaceuticals' most advanced therapeutic product, the broad-spectrum fluoroquinolone antibiotic finafloxacin, has moved into its first Phase III clinical trials, in the US and Canada for the treatment of ear infections.